Sagimet Biosciences Inc.

SGMT Healthcare Biotechnology

Sagimet Biosciences Inc.’s revenue for fiscal 2023 (year ended December 2023) was $2.0 million. In the quarter to June 2026, EPS grew 18.8% and free cash flow fell 22.0%, each against the same quarter a year earlier.

8.02 0.15 −1.84%
Market cap
$574.7M
P/E
0.0×
Fwd P/E
−2.3×
Dividend yield
—
F-score
n/a
Altman Z
2.50
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
13.06 22.82 20.34 45.02
Net Debt/EBITDA
8.18 10.81 8.82 15.16
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.31) (0.37) (0.26) (0.21)
Book value per Share
3.67 3.44 3.15 4.82
Free Cash Flow
(10.18) (11.83) (8.61) (11.10)
Other line items

Show all line items

Columns are period end dates